top of page

Hilde Cheroutre, Ph.D

Praespero - An Autoimmune Research Fund LOGO 10_rEVERSE.png

Hilde Cheroutre, Ph.D. Scientific Advisory Board Member, Praespero Professor, Center for Autoimmunity and Inflammation and Center for Cancer Immunotherapy, La Jolla Institute for Immunology.


Key Achievements

  • Named a Distinguished Fellow of the American Association of Immunologists (2024)

  • Recipient of the NIH Director's Pioneer Award (2009)

  • Discovered that retinoic acid, a vitamin A derivative, helps control inflammation, a finding Nature Medicine named a key biomedical advance of 2007

  • Identified a small protein that guides T cell education in the thymus, and showed that educated self-reactive T cells can eliminate pathogenic autoreactive T cells

  • Advancing educated T cell research toward human safety testing and first clinical trials


ABOUT 


A pioneering immunologist, Hilde Cheroutre investigates the root causes of autoimmunity and cancer at the La Jolla Institute for Immunology. Her career spans foundational work on antiviral proteins at Ghent University in Belgium and postdoctoral research at Caltech, where she helped reveal how specialized immune cells protect the gut. Her research has since focused on how immune cells defend the body at mucosal surfaces and how defects in T cell education can drive autoimmune and inflammatory disease.


Beyond the lab, Dr. Cheroutre has strengthened the global scientific community through international collaborations, training of young scientists, and her long-time leadership of the La Jolla Immunology Conference, where she introduced the annual "Frontier Lecture" to highlight how the immune system interacts with other biological systems. On Praespero's Scientific Advisory Board, she brings the pioneering, boundary-pushing thinking that Praespero exists to support.


With Praespero's funding, Dr. Cheroutre's team studied the human thymus and uncovered a small protein that guides T cell education. Disrupting it in mouse models produced aggressive, self-attacking T cells, while thymic-educated self-reactive T cells, abundant in the gut, were found to detect and eliminate pathogenic autoreactive T cells. These findings suggest that autoimmune disease and cancer risk can be set early in T cell development, pointing toward re-educating T cells rather than suppressing them. Her team is now isolating educated self-reactive T cells from human blood and testing them with patient-derived tissue and tumor biopsies, with clinical trials being planned in India, the UK and the US.


On Praespero's Scientific Advisory Board, Dr. Cheroutre brings the pioneering, boundary-pushing thinking that Praespero exists to support.

bottom of page